share_log

Needham Maintains Buy on Blueprint Medicines, Raises Price Target to $130

Benzinga ·  May 3 05:50

Needham analyst Ami Fadia maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and raises the price target from $97 to $130.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment